[Efficacy and Safety of Flumatinib and Imatinib as First-line Treatments for Newly-diagnosed Chronic Myeloid Leukemia in Chronic Phase: A Real-world Study].

Objective: To compare the efficacy and safety of flumatinib (FM) and imatinib (IM) as first-line treatment in newly-diagnosed patients with chronic myeloid leukemia in chronic phase (CML-CP) in real world.

Methods: A total of 84 newly-diagnosed CP-CML patients in our center from December 2019 to December 2022 were retrospectively analyzed. Among them, 32 cases received FM as first-line treatment, and 52 cases received IM.

Mosquito аbundance and species surveillance in St. Joseph County, Indiana, 1976-1997.

Background: Approximately twenty-one years of historical mosquito abundance and species surveillance data, collected by the University of Notre Dame and the St. Joseph County (IN) Health Department, from 1976 to 1997 are made available following a data rescue effort. St.

Metformin's effect on metabolic dysfunction-associated steatotic liver disease through the miR-200a-5p and AMPK/SERCA2b pathway.

Introduction: Metformin has shown benefits in treating metabolic dysfunction-associated steatotic liver disease (MASLD), but its mechanisms remain unclear. This study investigates miR-200a-5p's role in the AMPK/SERCA2b pathway to reduce liver fat accumulation and ER stress in MASLD.

Methods: A PA cell model induced by palmitic and oleic acids (2:1) was used to assess lipid accumulation via Oil Red O and Nile Red staining.

What Will Deliver the Best Bang-For-Your-Treatment-Buck? Treatment Effects of Physical Therapy Approaches to Managing Chronic Ankle Instability: A Network Meta-Analysis of Randomized Controlled Trials.

To evaluate the relative efficacy of various physical therapy interventions for chronic ankle instability (CAI). A network meta-analysis of randomized controlled trials. PubMed, Cochrane Library, Embase, Scopus, and CINAHL bibliographic databases were searched up to December 2023.

Novel research model for in vitro immunotherapy: co-culturing tumor organoids with peripheral blood mononuclear cells.

Tumor organoids have emerged as powerful tools for in vitro cancer research due to their ability to retain the structural and genetic characteristics of tumors. Nevertheless, the absence of a complete tumor microenvironment (TME) limits the broader application of organoid models in immunological studies. Given the critical role of immune cells in tumor initiation and progression, the co-culture model of organoids and peripheral blood mononuclear cells (PBMCs) may provide an effective platform for simulating the interactions between immune and tumor cells in vitro.